Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases.
BACKGROUND: Anti-angiogenic therapy with bevacizumab (an anti-vascular endothelial growth factor (VEGF) antibody) predominantly targets immature blood vessels. Bevacizumab has shown a survival benefit in non-small cell lung carcinoma (NSCLC) and has recently been demonstrated to be safe in patients...
Hlavní autoři: | Jubb, A, Cesario, A, Ferguson, M, Congedo, M, Gatter, K, Lococo, F, Mulè, A, Pezzella, F |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
2011
|
Podobné jednotky
-
Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases
Autor: Jubb, A, a další
Vydáno: (2011) -
Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas.
Autor: Passalidou, E, a další
Vydáno: (2002) -
Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas.
Autor: Passalidou, E, a další
Vydáno: (2002) -
Tumor necrosis factor receptor-associated protein 1(TRAP1) regulates genes involved in cell cycle and metastases.
Autor: Liu, D, a další
Vydáno: (2010) -
Vascular endothelial growth factor expression in lung cancer.
Autor: O'Byrne, K, a další
Vydáno: (1998)